
投項目不如投「成功基因」。在抗癌革命的長征中,漢康生技創辦人劉世高博士曾帶領做出歐盟批准新藥的團隊,二次創業的漢康生技,即將啟動一場「打世界盃」的抗癌長征。 本節目深入漢康的研發核心,與商務、研發領袖共同探討:如何透過數億美金的區域授權驗證,進一步撬動全球市場的增長潛力 ?為何 HCB101 的安全性數據能吸引美、日大廠的戰略關注? 漢康致力於將複雜的免疫學,翻譯成聽得懂的希望。在這裡,我們解讀數據爆發期的關鍵訊號,分享從實驗室到國際談判桌的實戰智慧。邀請您與漢康一起,掌握改變人類壽命與資本格局的領先基因。 漢康生技官網:www.hanchorbio.com/ 漢康生技LinkedIn:reurl.cc/7b19y9 本節目旨在透過科學導讀與商業邏輯分享,幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準,內容不構成... more
| Episodes | 2 | Founded | 13 days ago | Categories | MedicineLife SciencesScienceHealth & Fitness |
|---|

【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作
2025 年 6 月,漢康生技宣佈與復宏漢霖達成抗癌新藥 HCB101 的區域授權,總金額突破 2 億美元。這不僅是漢康的重要里程碑,更證明了臺灣生技研發實力已具備國際競爭力。本集節目特別邀請漢康生技商務開發長(CBO)叢越華博士,他擁有德國有機化學博士背景,並曾主導過數十億美元的國際授權案。叢博士將分享:
• 科學與使命: 為什麼「先天免疫」是癌症治療的下一個關鍵?
• 授權內幕: 為什麼復宏漢霖願意投資一家僅成立 5 年的 Sta... more
【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作
生技投資常被視為高風險的博弈,但在資深投資者眼中,這是一場關於「勝率」與「倍數」的賽局 。本集邀請漢康生技創辦人劉世高博士,以他帶領團隊研發出台灣首個獲歐盟批准創新藥的實戰經驗,剖析為何他選擇投入僅有 1.6% 企業敢挑戰的「多功能融合蛋白」賽道。
劉博士將分享生醫界獨特的「頭彩理論」:當一個標靶能同時啟動多種免疫機制,它的商業回報將不再是單一產品,而是具備全球競爭力的戰略資產。讓我們與漢康一起,看見數據背後的商業邏輯,讀懂這場... more
How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.
Apple Podcasts | #11 | |
Apple Podcasts | #75 |
Listeners, social reach, demographics and more for this podcast.
| Gender Skew | Location | Interests | |||
|---|---|---|---|---|---|
| Professions | Age Range | Household Income | |||
| Social Media Reach | |||||
Rephonic provides a wide range of podcast stats for 與漢康讀懂腫瘤免疫新藥的抗癌革命. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to 與漢康讀懂腫瘤免疫新藥的抗癌革命 and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.
Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for 與漢康讀懂腫瘤免疫新藥的抗癌革命, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.
Rephonic provides comprehensive predictive audience data for 與漢康讀懂腫瘤免疫新藥的抗癌革命, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.
To see how many followers or subscribers 與漢康讀懂腫瘤免疫新藥的抗癌革命 has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.
These podcasts share a similar audience with 與漢康讀懂腫瘤免疫新藥的抗癌革命:
1. Gooaye 股癌
與漢康讀懂腫瘤免疫新藥的抗癌革命 launched 13 days ago and published 2 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.
Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.
Rephonic pulls ratings and reviews for 與漢康讀懂腫瘤免疫新藥的抗癌革命 from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.
View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.
Rephonic provides full transcripts for episodes of 與漢康讀懂腫瘤免疫新藥的抗癌革命. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.